Montelukast Sodium/Mometasone furoate

孟鲁司特钠/莫米松糠酸酯

Report date: 2022/01/24 14:07:53

Base Information

Drug NameMontelukast Sodium/Mometasone furoate
Drug Alias Name孟鲁司特钠莫米松糠酸酯Mometasone furoate and Montelukast Sodium莫米松糠酸酯孟鲁司特钠Mometasone furoate/Montelukast Sodium莫米松糠酸酯/孟鲁司特钠 +[7] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionCysteinyl leukotriene receptor 1 antagonistsGlucocorticoid receptor agonists
TargetsCysteinyl leukotriene receptor 1Glucocorticoid receptor
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes MontelukastMometasone furoate
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme Corp
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A